nature portfolio

Corresponding author(s):	Zihuai He
Last updated by author(s):	Nov 2, 2022

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

< ∙	tっ	1		۲ı	~
.)	ıd	ш	1.5	ıI	CS

For	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
	\square The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	A description of all covariates tested
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

Software and code

Policy information about <u>availability of computer code</u>

Data collection

No software was used.

Data analysis

We have implemented GhostKnockoff in a computationally efficient R package that can be accessed at https://cran.r-project.org/web/packages/GhostKnockoff/.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio <u>guidelines for submitting code & software</u> for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The manuscript used summary statistics from existing studies from the UK Biobank available at https://pheweb.org/UKB-SAIGE/. The summary statistics from each GWAS for Alzheimer's disease can be found at https://ctg.cncr.nl/software/summary_statistics, https://www.niagads.org/datasets, and https://www.ebi.ac.uk/gwas/. Specifically, 1. The genome-wide survival association study performed by Huang et al. 2017 (NIAGADS ID: NG00058); 2. The genome-wide meta-analysis by

Jansen et al. 201944 (available through: https://ctg.cncr.nl/software/summary_statistics); 3. The genome-wide meta-analysis by Kunkle et al. 2019 (NIAGADS ID: NG00075); 4. The genome-wide meta-analysis by Schwartzentruber et al. 2021 (GWAS catalog ID: GCST90012877); 5. In-house genome-wide associations study imputed using the TOPMed reference panels (see Supplementary Table 3); 6-7. Two whole-exome sequencing analyses of data from ADSP by Bis et al. 2020 (NIAGADS ID: NG00065), and Le Guen et al. 2021 (NIAGADS ID: NG000112); 8. In-house whole-exome sequencing analysis of ADSP (NIAGADS ID: NG00067.v5). The single cell RNASeq data for the candidate genes is available in the GEO database under accession code GSE163577 [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE163577]. The results of our analysis of UK Biobank and AD genetics can be downloaded at: zihuaihelab.github.io.

Human research participants

Policy information about studies involving human research participants and Sex and Gender in Research.

Reporting on sex and gender

Population characteristics NA NA Recruitment Ethics oversight NA Note that full information on the approval of the study protocol must also be provided in the manuscript. Field-specific reporting Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection. X Life sciences For a reference copy of the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u> Life sciences study design All studies must disclose on these points even when the disclosure is negative. Sample size The paper focuses on method development, with applications to summary statistics that are publicly available. No individual level datasets were used. No data were excluded from the analysis. Data exclusions Replication NΑ

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems	Methods
n/a Involved in the study	n/a Involved in the study
Antibodies	ChIP-seq
Eukaryotic cell lines	Flow cytometry
Palaeontology and archaeology	MRI-based neuroimaging
Animals and other organisms	·
Clinical data	
Dual use research of concern	

Randomization

Blinding

NΑ

NΑ